Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study

被引：7

作者：

Matsumoto, Takashi ^{[1
]}

Shiota, Masaki ^{[1
]}

Nakamura, Motonobu ^{[2
]}

Yokomizo, Akira ^{[3
]}

Tomoda, Toshihisa ^{[4
]}

Sakamoto, Naotaka ^{[5
]}

Seki, Narihito ^{[6
]}

Hasegawa, Shuji ^{[7
]}

Yunoki, Takakazu ^{[8
]}

Harano, Masahiko ^{[9
]}

Kuroiwa, Kentaro ^{[10
]}

Eto, Masatoshi ^{[1
]}

机构：

[1] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan

[2] Natl Hosp Org Kyushu Canc Ctr, Dept Urol, Fukuoka, Japan

[3] Harasanshin Hosp, Div Urol, Fukuoka, Japan

[4] Oita Prefectural Hosp, Dept Urol, Oita, Japan

[5] Natl Hosp Org Kyushu Med Ctr, Dept Urol, Fukuoka, Japan

[6] Kyushu Cent Hosp, Dept Urol, Fukuoka, Japan

[7] Kitakyushu Municipal Med Ctr, Dept Urol, Kitakyushu, Fukuoka, Japan

[8] Japanese Red Cross Fukuoka Hosp, Dept Urol, Fukuoka, Japan

[9] JCHO Kyushu Hosp, Dept Urol, Kitakyushu, Fukuoka, Japan

[10] Miyazaki Prefectural Miyazaki Hosp, Dept Urol, Miyazaki, Japan

来源：

PROSTATE INTERNATIONAL | 2021年 / 9卷 / 02期

关键词：

Cabazitaxel; Castration-resistant prostate cancer; Efficacy; Safety; The elderly; DOCETAXEL; CHEMOTHERAPY;

D O I：

10.1016/j.prnil.2020.12.001

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Background: There is little data on the outcome of cabazitaxel (CBZ) treatment of elderly patients with castration-resistant prostate cancer (CRPC). This study assessed the efficacy and safety of CBZ chemotherapy in patients with CRPC aged 75 years or older in a multiinstitutional study. Methods: We retrospectively reviewed the 74 patients with CRPC treated with CBZ enrolled in 10 institutions. Clinicopathological backgrounds, prognosis including prostate-specific antigen decline, time to treatment failure, progression-free survival, overall survival, and safety profiles were compared between younger (<75 years) and elder (>= 75 years) patients. Results: In total, 74 patients were enrolled; 50 patients were younger than 75 years and 24 were >= 75 years. Clinicopathological characteristics were comparable between younger and elder patients, with the exception of serum albumin values at the time of CBZ treatment. The median prostate-specific antigen decline in younger and elder men was -8.8% and -32.3% from baseline, respectively. The median time to treatment failure, progression-free survival, and overall survival for younger and elder men were 0.24 and 0.33 years, 0.23 and 0.43 years, and 0.69 and 1.17 years, respectively. In addition, safety profiles were comparable between younger and elder patients. Conclusions: This multiinstitutional study suggests that patients with CRPC aged 75 years or older eligible for CBZ treatment can be treated safely and with noninferior efficacy compared with those younger than 75 years. (C) 2021 Asian Pacific Prostate Society. Published by Elsevier B.V.

引用

页码：96 / 100

页数：5

共 16 条

[1] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].